Skip to Main Content
Skip Nav Destination

Human Type 2 Innate Lymphoid Cells Are Antitumor Cytolytic Effector Cells

January 25, 2024

Major Finding: Human type 2 innate lymphoid cells (ILC2) improve immune control of leukemia and solid tumors in vivo.  

Concept: Human ILC2s can be expanded from peripheral blood and kill target cells via pyroptosis and apoptosis.

Impact: This study highlights the potential efficacy of an adoptive cell therapy based on ex vivo ILC2 expansion.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal